Premium
Nonplatinum‐based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma
Author(s) -
Kiyota Naomi,
Tahara Makoto,
Fujii Satoshi,
Kawashima Mitsuhiko,
Ogino Takashi,
Minami Hironobu,
Hayashi Ryuichi,
Ohtsu Atsushi
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23246
Subject(s) - medicine , docetaxel , irinotecan , neutropenia , chemotherapy , radiation therapy , oncology , leukopenia , surgery , cancer , colorectal cancer
BACKGROUND The efficacy and safety of chemotherapy with irinotecan plus docetaxel were retrospectively evaluated for olfactory neuroblastoma. METHODS Twelve patients with histologically proven advanced or metastatic olfactory neuroblastoma were treated with chemotherapy with irinotecan plus docetaxel at the study institution between 2001 and 2005. Of these, 7 patients with locoregional disease and no prior radiotherapy received irinotecan plus docetaxel followed by definitive radiotherapy, 1 with photon radiotherapy and 6 with proton radiotherapy, whereas 3 patients with distant metastases and 2 with locoregional disease who had received prior radiotherapy received irinotecan plus docetaxel only. RESULTS The most common toxicities of ≥grade 3 among the 12 patients receiving irinotecan plus docetaxel were leukopenia (33%), neutropenia (50%), febrile neutropenia (8%), and diarrhea (25%), all of which were manageable. Partial response was achieved in 3 patients, giving an overall response rate of 25%. The response rate was higher in patients aged <50 years (3 of 4 patients) compared with those aged >50 years (0 of 8 patients) ( P = .018). With a median follow‐up period of 22.2 months, the median progression‐free survival and overall survival were 13.6 months and 36.6 months, respectively. Of the 7 patients with locoregional disease also receiving definitive radiotherapy, the 2‐year survival rate was 100% and 6 patients were alive at the time of last follow‐up. CONCLUSIONS Chemotherapy for olfactory neuroblastoma with irinotecan plus docetaxel is safe and manageable. Patients aged <50 years may be sensitive to chemotherapy. Induction chemotherapy followed by definitive radiotherapy may represent a promising option for patients with locally advanced olfactory neuroblastoma. Cancer 2008. © 2008 American Cancer Society.